Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ergomed Clinical Research has entered into an agreement with Ferrer, a privately-held Spanish pharmaceutical company, to support further clinical studies of Lorediplon in patients with insomnia.
Subscribe to our email newsletter
Ferrer also announced it is collaborating with Ildong Pharmaceuticals, Korea.
Ergomed is working with Ferrer as the clinical development organization to conduct the multicenter, multinational, randomized Phase IIa Lorediplon trial in insomnia.
Under the terms of the agreement, Ergomed will assume a proportion of the clinical and regulatory costs of the Phase IIa trial in return for a share of future revenues received by Ferrer for Lorediplon in this indication.
Ergomed CEO Dr Miroslav Reljanovic noted the company is very pleased to co-invest with Ferrer in the development of Lorediplon, which has shown promising results in clinical trials to date.
"Our seventh co-development agreement establishes us as one of the leading worldwide companies completing deals under this innovative model," Dr Reljanovic added.
Under the terms of the Ildong agreement, Ferrer will be eligible to receive payments from the co-operation and license agreement covering countries within East Asia, including South Korea, China and Japan. Ildong will be responsible for the costs and activities related to development and regulatory approvals in their territory.